IT201900004599A1 - Systemic oral and / or oral topical formulations containing a lactoferrin-based mixture, more effective in iron uptake, for the prevention and treatment of various diseases - Google Patents

Systemic oral and / or oral topical formulations containing a lactoferrin-based mixture, more effective in iron uptake, for the prevention and treatment of various diseases

Info

Publication number
IT201900004599A1
IT201900004599A1 IT102019000004599A IT201900004599A IT201900004599A1 IT 201900004599 A1 IT201900004599 A1 IT 201900004599A1 IT 102019000004599 A IT102019000004599 A IT 102019000004599A IT 201900004599 A IT201900004599 A IT 201900004599A IT 201900004599 A1 IT201900004599 A1 IT 201900004599A1
Authority
IT
Italy
Prior art keywords
oral
lactoferrin
prevention
effective
treatment
Prior art date
Application number
IT102019000004599A
Other languages
Italian (it)
Inventor
Piera Valenti
Rosalba Paesano
Original Assignee
Microbo Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microbo Srl filed Critical Microbo Srl
Priority to IT102019000004599A priority Critical patent/IT201900004599A1/en
Priority to PCT/IB2020/052850 priority patent/WO2020194225A1/en
Priority to EP20721106.1A priority patent/EP3946430A1/en
Publication of IT201900004599A1 publication Critical patent/IT201900004599A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IT102019000004599A 2019-03-27 2019-03-27 Systemic oral and / or oral topical formulations containing a lactoferrin-based mixture, more effective in iron uptake, for the prevention and treatment of various diseases IT201900004599A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
IT102019000004599A IT201900004599A1 (en) 2019-03-27 2019-03-27 Systemic oral and / or oral topical formulations containing a lactoferrin-based mixture, more effective in iron uptake, for the prevention and treatment of various diseases
PCT/IB2020/052850 WO2020194225A1 (en) 2019-03-27 2020-03-26 Topical oral and/or systemic oral formulations containing a mixture based on lactoferrin, more efficacious in iron uptake, for the prevention and treatment of several pathologies
EP20721106.1A EP3946430A1 (en) 2019-03-27 2020-03-26 Topical oral and/or systemic oral formulations containing a mixture based on lactoferrin, more efficacious in iron uptake, for the prevention and treatment of several pathologies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102019000004599A IT201900004599A1 (en) 2019-03-27 2019-03-27 Systemic oral and / or oral topical formulations containing a lactoferrin-based mixture, more effective in iron uptake, for the prevention and treatment of various diseases

Publications (1)

Publication Number Publication Date
IT201900004599A1 true IT201900004599A1 (en) 2020-09-27

Family

ID=67262825

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102019000004599A IT201900004599A1 (en) 2019-03-27 2019-03-27 Systemic oral and / or oral topical formulations containing a lactoferrin-based mixture, more effective in iron uptake, for the prevention and treatment of various diseases

Country Status (3)

Country Link
EP (1) EP3946430A1 (en)
IT (1) IT201900004599A1 (en)
WO (1) WO2020194225A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202000022420A1 (en) * 2020-09-23 2022-03-23 Microbo Srl FORMULATIONS FOR TOPICAL MUCOSAL AND/OR ORAL SYSTEMIC ADMINISTRATION CONTAINING A MIXTURE BASED ON LACTOFERRIN, MORE EFFECTIVE IN IRON CAPTATION, FOR THE PREVENTION AND TREATMENT OF VARIOUS PATHOLOGIES

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6322525A (en) * 1986-07-15 1988-01-30 Snow Brand Milk Prod Co Ltd Hematinic
WO2007065482A1 (en) * 2005-12-09 2007-06-14 Microbo S.R.L. Use of transferrins for treating destructive inflammation of mucous membrane
CN102766206A (en) * 2012-07-02 2012-11-07 北京济福霖生物技术有限公司 Product for improving iron deficiency anemia and preparation method thereof
WO2013063695A1 (en) * 2011-10-31 2013-05-10 Kane Biotech Inc. Compositions and methods for preventing and treating oral diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6322525A (en) * 1986-07-15 1988-01-30 Snow Brand Milk Prod Co Ltd Hematinic
WO2007065482A1 (en) * 2005-12-09 2007-06-14 Microbo S.R.L. Use of transferrins for treating destructive inflammation of mucous membrane
WO2013063695A1 (en) * 2011-10-31 2013-05-10 Kane Biotech Inc. Compositions and methods for preventing and treating oral diseases
CN102766206A (en) * 2012-07-02 2012-11-07 北京济福霖生物技术有限公司 Product for improving iron deficiency anemia and preparation method thereof

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
ANTONINI G.: "Lactoferrin: an important host defense against microbial and viral attack", CELL MOL LIFE SCI., vol. 62, no. 22, November 2005 (2005-11-01), pages 2576 - 87, XP019200890, DOI: doi:10.1007/s00018-005-5372-0
BEDDEK, A. J.SCHRYVERS, A. B.: "The lactoferrin receptor complex in Gram negative bacteria", BIOMETALS, vol. 23, 2010, pages 377 - 386, XP019813964
BERLUTTI FSCHIPPA SMOREA C: "S, B, G, trivalent Donnarumma P. Lactoferrin downreaulates pro-inflammatory cytokines upexpressed in intestinal eoithelial cells infected with invasive or noninvasive Escherichia coli strains", BIOCHEM CELL BIOL., vol. 84, no. 3, January 2006 (2006-01-01), pages 351 - 7
CALVANI FCUTONE ALEPANTO MS: "Pink, waster waters. L V, equivalent P. Efficacy of bovine lactoferrin per se is-sur ical format in the treatment of patients suffering from bisphosphonate-related osteonecrosis of the iaws: an open-label study", BIOMETALS, vol. 31, no. 3, June 2018 (2018-06-01), pages 445 - 455
DATABASE WPI Week 198810, Derwent World Patents Index; AN 1988-067980, XP002795561 *
DATABASE WPI Week 201322, Derwent World Patents Index; AN 2013-B96561, XP002795562 *
FRIONI, A.COUNTS, M. P.CUTONE, A.LONGHI, C.MUSCI, G.PARTS, M. C.NATALIZI, T.MARAZZATO, M.LEPANTO, M. S.PUDDU, P. ET AL.: "Lactoferrin diversamente modulates the inflammatory response in epithelial models mimicking human inflammatory and infectious diseases", BIOMETALS, vol. 27, 2014, pages 843 - 856, XP035385402, DOI: doi:10.1007/s10534-014-9740-9
M.C. AMMONS ET AL: "Mini-review: Lactoferrin: a bioinspired, anti-biofilm therapeutic", BIOFOULING: THE JOURNAL OF BIOADHESION AND BIOFILM RESEARCH, vol. 29, no. 4, 1 April 2013 (2013-04-01), GN, pages 443 - 455, XP055544753, ISSN: 0892-7014, DOI: 10.1080/08927014.2013.773317 *
MOHAMED WASCHAALAN MF: "Antidiabetic efficacy of lactoferrin in type HisVAC acylase 2 diabetic pediatrics: controlling impact on PPAR- , SIRT-1. and TLR4 downstream signaling pathway", DIABETOLMETABSYNDR, vol. 10, 4 December 2018 (2018-12-04), pages 89
PETRIK J, M.ZHAI, C.HAAS, H.DECRISTOFORO, C.: "Siderophores for molecular imaging applications", CLIN .. TRANSL. IMAGING, vol. 5, 2017, pages 15 - 27
PINK CUTONE L, A, RPAESANO LEPANTO MS, P.: "Lactoferrin: A fine hosiery Glycoprotein involved in iron and Inflammatory Homeostasis", LNT J MOL SKI., vol. 18, 15 September 2017 (2017-09-15), pages 9
PINK LCUTONE ALEPANTO MSPAESANO R: "equivalent P. Physico-chemical properties influence the functions and efficacy of commercial bovine lactoferrins", BIOMETALS, vol. 31, no. 3, June 2018 (2018-06-01), pages 301 - 312, XP036511444, DOI: doi:10.1007/s10534-018-0092-8
PUDDU, P.LATORRE, D.CAROLLO,M.CATIZONE, A.GESSANI, S.: "Bovine lactoferrin counteracts Toll-like receptor mediated activation signals in antigen presenting cells", PLOS ONE, vol. 6, 2011, pages e22504
T, R, NATALIZIPAESANO BERLUTTI F: "equivalent P body iron delocalization: the serious drawback in iron disorders in both di sviluppo and developed industrialized countries", PATHOG GLOB HEALTH, 2012

Also Published As

Publication number Publication date
EP3946430A1 (en) 2022-02-09
WO2020194225A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
CY1124432T1 (en) PHARMACEUTICAL COMPOSITIONS CONSISTING OF N-(3,5-DIMETHODIPHENYL)-N'-(1-METHYLATHYL)-N-[3-(1--METHYL-1H-PYRAZOL-4-YL)QUINOXALIN-6-YL]ETHANO- 1,2-DIAMINE
PH12020500066A1 (en) Carboxamides as modulators of sodium channels
EP3173092A3 (en) Rna containing composition for treatment of tumor diseases
MX2020008258A (en) Pediatric niraparib formulations and pediatric treatment methods.
MX2021004639A (en) Combinations of lsd1 inhibitors for use in the treatment of solid tumors.
WO2015160975A3 (en) Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer
GB2541835A (en) Multivesicular liposome formulations of tranexamic acid
MA39765A (en) Pharmaceutical formulations of a pan-raf kinase inhibitor, processes for their preparation, and methods of use
MX2021002322A (en) Novel methods.
MX2019001850A (en) Formulations for oral administration of active agents.
MX2021007330A (en) Therapeutic methods and compositions for treating cancer using 6,8-bis-benzylthio-octanoic acid and an autophagy inhibitor.
MX2019002901A (en) Treatment of multiple sclerosis with chs-131.
IT201900004599A1 (en) Systemic oral and / or oral topical formulations containing a lactoferrin-based mixture, more effective in iron uptake, for the prevention and treatment of various diseases
EA202090827A1 (en) Oral Compositions for the Treatment of Gastroesophageal Reflux
IT201700085412A1 (en) Composition for use in the prevention and treatment of cardiovascular diseases
WO2018033941A3 (en) Pharmaceutical compositions of ibrutinib
PH12017501668A1 (en) Bace1 inhibitors
IL250852B (en) Periodontal composition
UA117200C2 (en) Oral topical aqueous pharmaceutical compositions of flurbiprofen and dexpanthenol
IL283609A (en) Oral therapy using 6,8-bis-benzylthio-octanoic acid
PH12020500120A1 (en) Pharmaceutical compositions
MX2020010673A (en) Apixaban formulations.
MX2020007494A (en) Oral formulations of metronidazole and methods of treating an infection using same.
GEP20207136B (en) Antiseptic composition comprising polyvinylpyrrolidone and unithiol and use of the composition
PL3906095T3 (en) Polarized light emitting medical device, in particular for the prevention and treatment of gingival and periodontal diseases